IP Library Granted Patent US 7,932,083
Granted Patent B2
US 7,932,083 · App. 10/577,655 · Granted Apr 26, 2011

DNA participating in hydroxylation of macrolide compound

Assignees: Mercian Corporation; Eisai R&D Management Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,932,083
App. No.
10/577,655
Granted
Apr 26, 2011
Kind
B2
Abstract

The present invention provides a DNA participating in biological transformation of a macrolide compound 11107B. The present invention provides, particularly, a DNA participating in biological transformation of a macrolide compound 11107B represented by the formula (I) into a 16-position hydroxy macrolide compound 11107D represented by the formula (II), the DNA encoding a protein having 16-position hydroxylating enzymatic activity or ferredoxin, to a method of isolating the DNA, to a protein encoded by the DNA, a plasmid carrying the DNA, a transformant obtained by transforming using the plasmid and a method of producing a 16-position hydroxy compound by using the transformant.

Claims (19)

1. A DNA participating in biological transformation of a macrolide compound (hereinafter referred to as a macrolide compound 11107B) represented by the formula (I):

into a 16-position hydroxy macrolide compound represented by the formula (II):

the DNA being an isolated and pure DNA comprising a DNA encoding a protein having

16-position hydroxylating enzymatic activity which is characterized by the following (a), (b), or (c):

(a) a DNA encoding a protein having the enzymatic activity to hydroxylate the 16-position of the macrolide compound 11107B, wherein the DNA is selected from the group consisting of (1) a continuous nucleotide sequence from base 1322 to base 2548 of SEQ ID NO: 1; (2) a continuous nucleotide sequence from base 420 to base 1604 of SEQ ID NO: 4; and (3) a continuous nucleotide sequence from base 172 to base 1383 of SEQ ID NO: 7;

(b) a DNA which has a nucleotide sequence having 90% or more identity over the full length sequence with the DNA described in (a);

(c) a DNA encoding a protein having the same amino acid sequence as the protein encoded by the DNA described in (a) or (b) though it does not have 90% or more identity with the DNA described in (a) because of the degeneracy of a gene codon.

2. A self-replicative or integrating replicative recombinant plasmid carrying the DNA as claimed in claim 1 .

3. An isolated transformant obtained by transformation of the recombinant plasmid of claim 2 .

4. The DNA according to claim 1 , wherein the DNA comprises bases 1322-2548 of SEQ ID NO: 1.

5. The DNA according to claim 1 , wherein the DNA encodes a polypeptide comprising SEQ ID NO: 2.

6. The DNA according to claim 1 , wherein the DNA consists of bases 1322-2548 of SEQ ID NO: 1.

7. The DNA according to claim 1 , wherein the DNA encodes a polypeptide consisting of SEQ ID NO: 2.

8. The DNA according to claim 1 , wherein said identity in (b) and (c) of claim 1 is 95% or more.

9. A DNA comprising

(a) a DNA encoding a protein, wherein the DNA is selected from the group consisting of (1) a continuous nucleotide sequence from base 1322 to base 2548 of SEQ ID NO: 1; (2) a continuous nucleotide sequence from base 420 to base 1604 of SEQ ID NO: 4; and a continuous nucleotide sequence from base 172 to base 1383 of SEQ ID NO: 7;

(b) a DNA which has a nucleotide sequence having 90% or more identity over the full length sequence with the DNA described in (a); or

(c) a DNA encoding a protein having the same amino acid sequence as the protein encoded by the DNA described in (a) or (b) though it does not have 90% or more identity with the DNA described in (a) because of the degeneracy of a gene codon.

10. The DNA according to claim 9 , wherein said identity in (b) and (c) of claim 9 is 95% or more.

Assignments (7)
CHANGE OF ADDRESS Recorded Mar 4, 2022
From: MICROBIOPHARM JAPAN CO., LTD.
To: MICROBIOPHARM JAPAN CO., LTD.
Reel/Frame 059792/0794 →
CHANGE OF NAME AND ADDRESS Recorded Mar 4, 2022
From: MICROBIOPHARM JAPAN CO., LTD.
To: SANLI HOLDINGS CO., LTD.
Reel/Frame 059793/0517 →
SPLIT & SUCCESSION Recorded Mar 4, 2022
From: SANLI HOLDINGS CO., LTD.
To: MICROBIOPHARM JAPAN CO., LTD.
Reel/Frame 059318/0609 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2012
From: MERCIAN CORPORATION; EISAI R&D MANAGEMENT CO., LTD.
To: MICROBIOPHARM JAPAN CO., LTD.
Reel/Frame 027691/0455 →
CORRECTIVE ASSIGNMENT TO CORRECT THE EXECUTION DATE OF ASSIGNOR PREVIOUSLY RECORDED ON REEL 022643 FRAME 0291. ASSIGNOR(S) HEREBY CONFIRMS THE EXECUTION DATE SHOULD READ 04/23/2009. Recorded Jun 16, 2009
From: EISAI CO. LTD.
To: EISAI R&D MANAGEMENT CO., LTD.
Reel/Frame 022833/0682 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2009
From: EISAI CO. LTD.
To: EISAI R&D MANAGEMENT CO., LTD.
Reel/Frame 022643/0291 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2006
From: MACHIDA, KAZUHIRO; NAKASHIMA, TAKASHI; ARITOKU, YASUHIDE; TSUCHIDA, TOSHIO
To: MERCIAN CORPORATION; EISAI CO., LTD.
Reel/Frame 017876/0610 →
Priority Claims (1)
JP 2003-396828 · Nov 27, 2003 · national
Continuity (1)
Related Publication 20080070286A1 · Mar 20, 2008